Original from: Genomeweb
Thermo Fisher Scientific said on Tuesday that it received CE-IVD marking for the Ion Torrent Genexus Dx Integrated Sequencer this month and is making the platform commercially available for diagnostic testing and clinical research.
"With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital — including regional and community hospitals — can bring [next-generation sequencing] in house, giving clinicians access to timely, comprehensive genomic profiling results," said Garret Hampton, president of clinical NGS and oncology at Thermo Fisher, in a statement.
The company said it is also developing a sample-to-report diagnostic workflow and a portfolio of clinically validated assays for the Genexus, including comprehensive genomic profiling and hemato-oncology assays.
Thermo Fisher has been offering the research-use-only version of the Ion Torrent Genexus since its launch in late 2019.
Source: Thermo Fisher Scientific Obtains CE Mark for Ion Torrent Genexus Dx Integrated Sequencer
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.